Compare PROP & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | ALDX |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.6M | 95.7M |
| IPO Year | 2008 | 2014 |
| Metric | PROP | ALDX |
|---|---|---|
| Price | $1.30 | $1.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $6.75 | $5.50 |
| AVG Volume (30 Days) | ★ 7.2M | 5.9M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $81.83 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $1.22 | $1.07 |
| 52 Week High | $4.68 | $6.18 |
| Indicator | PROP | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 35.49 |
| Support Level | N/A | $1.48 |
| Resistance Level | $2.11 | $2.33 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.10 | 0.13 |
| Stochastic Oscillator | 5.20 | 82.32 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.